ストックスクリーナーアプリを入手
2.01
0.50%
-0.01
アフターアワーズ：
2.01
前日終値:
$2.02
開ける：
$1.99
24時間の取引高:
597.42K
Relative Volume:
0.50
時価総額：
$137.41M
収益：
$488.00K
当期純損益:
$-41.44M
株価収益率:
-2.1613
EPS:
-0.93
ネットキャッシュフロー:
$-31.47M
1週間 パフォーマンス:
+1.52%
1か月 パフォーマンス:
+25.62%
6か月 パフォーマンス:
-3.37%
1年 パフォーマンス:
-43.85%
1日の値動き範囲:
$1.91
$2.02
1週間の範囲:
$1.79
$2.055
52週間の値動き範囲:
$1.48
$4.555
Cardiff Oncology Inc Stock (CRDF) Company Profile
名前
Cardiff Oncology Inc
セクター
電話
858-952-7570
住所
11055 FLINTKOTE AVENUE, SAN DIEGO, CA
Compare CRDF vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CRDF
Cardiff Oncology Inc
|
2.01 | 138.10M | 488.00K | -41.44M | -31.47M | -0.93 |
|
VRTX
Vertex Pharmaceuticals Inc
|
492.38 | 126.81B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
774.66 | 81.62B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.09 | 45.97B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.43 | 42.76B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
298.91 | 33.88B | 5.36B | 287.73M | 924.18M | 2.5229 |
Cardiff Oncology Inc Stock (CRDF) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-05 | 開始されました | Noble Capital Markets | Outperform |
| 2025-07-08 | 開始されました | Ladenburg Thalmann | Buy |
| 2025-06-24 | 開始されました | Jefferies | Hold |
| 2024-09-06 | 開始されました | Craig Hallum | Buy |
| 2022-01-05 | 開始されました | William Blair | Outperform |
| 2021-12-08 | 開始されました | Robert W. Baird | Outperform |
| 2021-08-09 | 再開されました | Maxim Group | Buy |
| 2020-10-22 | 開始されました | H.C. Wainwright | Buy |
| 2020-10-08 | 開始されました | Piper Sandler | Overweight |
すべてを表示
Cardiff Oncology Inc (CRDF) 最新ニュース
Jobs Data: Is Cardiff Oncology Inc undervalued by DCF analysisWatch List & Low Risk High Reward Ideas - baoquankhu1.vn
Can Cardiff Oncology Inc reach all time highs this yearGDP Growth & Daily Growth Stock Investment Tips - baoquankhu1.vn
What is Zacks Research's Forecast for CRDF FY2027 Earnings? - MarketBeat
CRDF Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Cardiff Oncology (NASDAQ:CRDF) Upgraded at Wall Street Zen - MarketBeat
Cardiff Oncology, Inc. (CRDF) - Minichart
Cardiff Oncology, Inc. (NASDAQ:CRDF) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
HC Wainwright Issues Optimistic Outlook for CRDF Earnings - MarketBeat
Analysts Offer Insights on Healthcare Companies: IQVIA Holdings (IQV), RxSight (RXST) and Cardiff Oncology (CRDF) - The Globe and Mail
Cardiff Oncology to Participate in Three Upcoming Investor Conferences - GlobeNewswire
Cardiff Oncology Spotlights Onvansertib Data at Oppenheimer: 72% ORR in RAS-Mutant mCRC - Defense World
CRDF: Onvansertib shows 72% ORR and robust PFS in RAS-mutated mCRC, advancing to phase III trials - TradingView
Piper Sandler Has Lowered Expectations for Cardiff Oncology (NASDAQ:CRDF) Stock Price - MarketBeat
CRDF: Today's Analyst Ratings and Price Target Adjustment | CRDF Stock News - GuruFocus
Cardiff Oncology advances onvansertib program in colorectal cancer - TipRanks
3 ‘Strong Buy’ Stocks to Buy Today, 2/25/2026, According to Top Analysts - TipRanks
Onvansertib Phase 2 results boost Cardiff Oncology (NASDAQ: CRDF) plans - Stock Titan
Cardiff Oncology Reports Full Year 2025 Results And Provides Business Update - Nasdaq
Cardiff Oncology Q4 2025 Results: Loss of $7.2M Beats Analyst Forecasts | Financial ReportNews and Statistics - IndexBox
Cardiff Oncology earnings beat by $0.08, revenue topped estimates - Investing.com Canada
Cardiff Oncology (NASDAQ:CRDF) Announces Quarterly Earnings Results - MarketBeat
Cardiff Oncology: Fourth Quarter Financial Results Overview - Bitget
Cardiff Oncology: Q4 Earnings Snapshot - marketscreener.com
Onvansertib Phase 2 results and 2025 loss at Cardiff Oncology (NASDAQ: CRDF) - Stock Titan
Cardiff Oncology Reports Full Year 2025 Results and Provides Business Update - GlobeNewswire
Cardiff Oncology, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
Cardiff Oncology to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference - ChartMill
Market Wrap: Does Cardiff Oncology Inc have consistent dividend growthEarnings Recap Report & Growth Focused Stock Reports - baoquankhu1.vn
Cardiff Oncology (CRDF) CAO awarded 200,000 stock options with staged vesting - Stock Titan
Why Cardiff Oncology Inc. (XE7C) stock could be next leaderWeekly Trend Recap & Growth Focused Stock Reports - mfd.ru
Can Cardiff Oncology Inc. stock reach $100 price targetMarket Activity Recap & Safe Entry Trade Signal Reports - mfd.ru
Will Cardiff Oncology Inc. stock outperform tech sector in 2025Weekly Stock Report & Free Community Supported Trade Ideas - mfd.ru
Will Cardiff Oncology Inc. outperform its industry peersQuarterly Portfolio Report & Precise Buy Zone Identification - mfd.ru
Cardiff Oncology, Inc. (NASDAQ:CRDF) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
FY2027 Earnings Estimate for CRDF Issued By Zacks Small Cap - MarketBeat
CRDF: New CEO Presents Phase II Readout - Yahoo Finance
Will Cardiff Oncology Inc. (XE7C) stock justify high valuationM&A Rumor & Growth Focused Entry Reports - mfd.ru
Leadership Turmoil Clouds Clinical Progress at Cardiff Oncology - AD HOC NEWS
Ideas Watch: Is Cardiff Oncology Inc likely to announce a buybackWeekly Gains Summary & Safe Entry Trade Reports - baoquankhu1.vn
Cardiff Oncology (CRDF) Is Down 43.9% After Advancing Onvansertib And Reshuffling Leadership Team - Yahoo Finance
Cardiff Oncology (CRDF) Valuation Check After New Onvansertib Phase 2 Data And Leadership Changes - simplywall.st
Cardiff Oncology Faces Turbulence Amid Leadership Changes - StocksToTrade
CRDF: HC Wainwright & Co. Reiterates Buy Rating with $10 Price T - GuruFocus
H.C. Wainwright reiterates Buy rating on Cardiff Oncology stock at $10 - Investing.com Canada
Cardiff Oncology (CRDF) Stock Drop Presents New Investment Oppor - GuruFocus
Why Did Cardiff Oncology Stock Plunge On Tuesday?Cardiff Oncology (NASDAQ:CRDF) - Benzinga
Investors Buy High Volume of Cardiff Oncology Call Options (NASDAQ:CRDF) - Defense World
Cardiff Oncology appoints interim CEO amid leadership transition By Investing.com - Investing.com India
Cardiff To Pursue Narrower CRC Market For Onvansertib As Top Execs Step Down - Citeline News & Insights
Cardiff Oncology Overhauls Leadership to Advance Onvansertib - TipRanks
Favorite son in PLK1? Cardiff dips as phase II CRC bid advances - BioWorld MedTech
Cardiff Oncology Inc (CRDF) 財務データ
収益
当期純利益
現金流量
EPS
1.57%
0.40%
大文字化:
|
ボリューム (24 時間):